These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Noninvasive visualization and quantification of tumor αVβ3 integrin expression using a novel positron emission tomography probe, 64Cu-cyclam-RAFT-c(-RGDfK-)4. Jin ZH; Furukawa T; Galibert M; Boturyn D; Coll JL; Fukumura T; Saga T; Dumy P; Fujibayashi Y Nucl Med Biol; 2011 May; 38(4):529-40. PubMed ID: 21531290 [TBL] [Abstract][Full Text] [Related]
4. In vivo optical imaging of integrin alphaV-beta3 in mice using multivalent or monovalent cRGD targeting vectors. Jin ZH; Josserand V; Foillard S; Boturyn D; Dumy P; Favrot MC; Coll JL Mol Cancer; 2007 Jun; 6():41. PubMed ID: 17565663 [TBL] [Abstract][Full Text] [Related]
5. Clustering and internalization of integrin alphavbeta3 with a tetrameric RGD-synthetic peptide. Sancey L; Lucie S; Garanger E; Elisabeth G; Foillard S; Stéphanie F; Schoehn G; Guy S; Hurbin A; Amandine H; Albiges-Rizo C; Corinne AR; Boturyn D; Didier B; Souchier C; Catherine S; Grichine A; Alexeï G; Dumy P; Pascal D; Coll JL; Jean-Luc C Mol Ther; 2009 May; 17(5):837-43. PubMed ID: 19259068 [TBL] [Abstract][Full Text] [Related]
6. Optical imaging of integrin alphavbeta3 expression with near-infrared fluorescent RGD dimer with tetra(ethylene glycol) linkers. Liu Z; Liu S; Niu G; Wang F; Liu S; Chen X Mol Imaging; 2010 Feb; 9(1):21-9. PubMed ID: 20128995 [TBL] [Abstract][Full Text] [Related]
7. In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in brain tumor xenografts. Chen X; Conti PS; Moats RA Cancer Res; 2004 Nov; 64(21):8009-14. PubMed ID: 15520209 [TBL] [Abstract][Full Text] [Related]
8. Reduction of renal uptake of 111In-DOTA-labeled and A700-labeled RAFT-RGD during integrin αvβ3 targeting using single photon emission computed tomography and optical imaging. Briat A; Wenk CH; Ahmadi M; Claron M; Boturyn D; Josserand V; Dumy P; Fagret D; Coll JL; Ghezzi C; Sancey L; Vuillez JP Cancer Sci; 2012 Jun; 103(6):1105-10. PubMed ID: 22448775 [TBL] [Abstract][Full Text] [Related]
9. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. Janssen ML; Oyen WJ; Dijkgraaf I; Massuger LF; Frielink C; Edwards DS; Rajopadhye M; Boonstra H; Corstens FH; Boerman OC Cancer Res; 2002 Nov; 62(21):6146-51. PubMed ID: 12414640 [TBL] [Abstract][Full Text] [Related]
10. Spectroscopically well-characterized RGD optical probe as a prerequisite for lifetime-gated tumor imaging. Mathejczyk JE; Pauli J; Dullin C; Napp J; Tietze LF; Kessler H; Resch-Genger U; Alves F Mol Imaging; 2011 Dec; 10(6):469-80. PubMed ID: 22201538 [TBL] [Abstract][Full Text] [Related]
11. αVβ3 Integrin-Targeted Radionuclide Therapy with 64Cu-cyclam-RAFT-c(-RGDfK-)4. Jin ZH; Furukawa T; Degardin M; Sugyo A; Tsuji AB; Yamasaki T; Kawamura K; Fujibayashi Y; Zhang MR; Boturyn D; Dumy P; Saga T Mol Cancer Ther; 2016 Sep; 15(9):2076-85. PubMed ID: 27422811 [TBL] [Abstract][Full Text] [Related]
12. Activatable iRGD-based peptide monolith: Targeting, internalization, and fluorescence activation for precise tumor imaging. Cho HJ; Lee SJ; Park SJ; Paik CH; Lee SM; Kim S; Lee YS J Control Release; 2016 Sep; 237():177-184. PubMed ID: 27349354 [TBL] [Abstract][Full Text] [Related]
13. 67Cu-Radiolabeling of a multimeric RGD peptide for αVβ3 integrin-targeted radionuclide therapy: stability, therapeutic efficacy, and safety studies in mice. Jin ZH; Furukawa T; Ohya T; Degardin M; Sugyo A; Tsuji AB; Fujibayashi Y; Zhang MR; Higashi T; Boturyn D; Dumy P; Saga T Nucl Med Commun; 2017 Apr; 38(4):347-355. PubMed ID: 28291159 [TBL] [Abstract][Full Text] [Related]
14. Near-infrared optical imaging of integrin alphavbeta3 in human tumor xenografts. Wang W; Ke S; Wu Q; Charnsangavej C; Gurfinkel M; Gelovani JG; Abbruzzese JL; Sevick-Muraca EM; Li C Mol Imaging; 2004 Oct; 3(4):343-51. PubMed ID: 15802051 [TBL] [Abstract][Full Text] [Related]
15. Fluorescence reflectance imaging of macrophage-rich atherosclerotic plaques using an alphavbeta3 integrin-targeted fluorochrome. Waldeck J; Häger F; Höltke C; Lanckohr C; von Wallbrunn A; Torsello G; Heindel W; Theilmeier G; Schäfers M; Bremer C J Nucl Med; 2008 Nov; 49(11):1845-51. PubMed ID: 18927332 [TBL] [Abstract][Full Text] [Related]
16. Integrin-targeted delivery into cancer cells of a Pt(IV) pro-drug through conjugation to RGD-containing peptides. Massaguer A; González-Cantó A; Escribano E; Barrabés S; Artigas G; Moreno V; Marchán V Dalton Trans; 2015 Jan; 44(1):202-12. PubMed ID: 25369773 [TBL] [Abstract][Full Text] [Related]
17. alpha(v)beta(3) Integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide. Yoshimoto M; Ogawa K; Washiyama K; Shikano N; Mori H; Amano R; Kawai K Int J Cancer; 2008 Aug; 123(3):709-15. PubMed ID: 18498129 [TBL] [Abstract][Full Text] [Related]